Biotechnology

JBS is entering the cultivated protein market with the acquisition of BioTech Foods and the construction of a plant in Europe

The new production plant in Spain will scale up production. The Company is also going to build a research & development center in biotechnology and cultivated protein inBrazil.  The investments total US$100 million  SÃO PAULO, Nov. 18, 2021 /PRNewswire/ -- JBS, the largest global protein compa...

2021-11-18 22:00 2253

Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing

NEW YORK and HONG KONG, Nov. 18, 2021 /PRNewswire/ -- Treadwell Therapeutics ("Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, today announced the closing of an oversubscribed Series B financing, which raised more than$91...

2021-11-18 20:00 2052

Prenetics Circle HealthPod joins forces with Ian Chan, member of popular boy group "Mirror" to achieve zero distancing

* Circle HealthPod is one of the world's most advanced home detection systems * Technology developed by the University of Oxford, with PCR-quality results in around 20 minutes * Ian sings the song "It's a Brand New Day" to empower individuals to resume normal life and drive healthier communi...

2021-11-18 09:08 2292

Silk Medical Aesthetics Announces Feasibility Clinical Trial Results for its All-Natural Dermal Filler

BOSTON, Nov. 18, 2021 /PRNewswire/ -- Silk Medical Aesthetics, alongside sister companyEvolved by Nature, the developer of Activated Silk™ biotechnology, announced today the results of a 44-patient feasibility study under an FDA-approved IDE clinical trial for its all-natural dermal filler for N...

2021-11-18 08:20 1490

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

GAITHERSBURG, Md. and PUNE, India, Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine m...

2021-11-17 23:23 2379

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

NANJING, China, Nov. 17, 2021 /PRNewswire/ -- OncoOne , a biotechnology company focused on discovering precision medicines for cancer and other indications andGenScript ProBio , a leading CDMO in biologics and gene cell therapy, today an...

2021-11-17 22:00 1213

Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2022 Financial Results

HONG KONG, Nov. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...

2021-11-17 20:00 1769

European Wellness Join Forces with Heidelberg University Germany in Safety and Toxicity Tests for Preclinical Anti-Aging Peptides Studies

HEIDELBERG, Germany, Nov. 17, 2021 /PRNewswire/ -- European Wellness Academy (EWA), a member of European Wellness Biomedical Group (EWBG), recently signed its second research contract involving General In Vitro/In Vivo Safety and Toxicity Tests for Preclinical Studies of Regenerative Peptides wit...

2021-11-17 16:51 1632

BioAgilytix Secures Significant New Investment from Global Investor Cinven to Fuel Continued Long-Term Growth

Investment Will Provide BioAgilytix with Additional Resources to Invest in Core Business and Drive Growth DURHAM, N.C. and BRUSSELS, Belgium and LONDON, Nov. 17, 2021 /PRNewswire/ -- BioAgilytix, a leading global contract research organization (CRO), today announced an agreement to be further ca...

2021-11-17 15:00 2021

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

SINGAPORE, Nov. 17, 2021 /PRNewswire/ -- OncoOne , a biotechnology company focused on discovering precision medicines for cancer and other indications andGenScript ProBio , a leading CDMO in biologics and gene cell therapy, today announc...

2021-11-17 09:10 1404

Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine

TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burdens, recently announced that the c...

2021-11-17 09:00 1878

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe

* The therapy aims to re-energize a patient's immune system to fight cancer tumors * Initial commercialization will target leading oncology centers in Germany, France, Italy, and Spain LAKEWOOD, Colo. and SAN DIEGO, Nov. 16, 2021 /PRNewswire/ --Terumo Blood and Cell Technologies

2021-11-17 00:00 1451

Sofwave™ Announces FDA clearance of New Lifting Indications for Eyebrow, Sub-Mental (beneath the chin) and Neck Facial Areas

The new indications include Eyebrow lifts and lifting of Lax tissue of the Submental and Neck Areas 80% of patients participating in a multi-site clinical trial saw improvement in just 12 weeks TUSTIN, Calif., Nov. 16, 2021 /PRNewswire/ -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in...

2021-11-16 23:23 1738

FibroBiologics Secures $100 Million Capital Commitment from GEM as Company Seeks to Go Public

The Company plans to go public via SPAC, reverse merger, or a direct listing HOUSTON, Nov. 16, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic cures for chronic diseases, announced today that it has signed an agreement with GEM Global Y...

2021-11-16 23:20 1247

FibroBiologics Secures $100 Million Capital Commitment from GEM as Company Seeks to Go Public

The Company plans to go public via SPAC, reverse merger, or a direct listing HOUSTON, Nov. 16, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic cures for chronic diseases, announced today that it has signed an agreement with GEM Global Y...

2021-11-16 23:07 1082

Delivering Health with Science: Huison Virgin DHA at the World Congress of Omega-3 Science & Technology

XIAMEN, China, Nov. 16, 2021 /PRNewswire/ -- The World Congress of Omega-3 Science & Technology, hosted by ISOR, was webcast worldwide onNovember 13 and November 14, 2021. It gathered 28 top experts and heads of relevant industry organizations from around the world who are deeply engaged in Omega...

2021-11-16 21:30 1136

Happiness Development Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

NANPING, China, Nov. 16, 2021 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"),(NASDAQ: HAPP) announced today that the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") onNovember 11, 2021, no...

2021-11-16 21:00 1213

Molecular Stethoscope, Inc. Announces Presentation of Primary Sclerosing Cholangitis (PSC) Study at the AASLD Liver Meeting 2021

Study results demonstrate the utility of the Company's Next-Generation cf-mRNA Liquid Biopsy Technology Platform for the characterization of PSC PALO ALTO, Calif., Nov. 16, 2021 /PRNewswire/ -- Molecular Stethoscope, Inc., a Precision Medicine biotechnology company, announces presentation of its ...

2021-11-16 19:00 990

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment ofJohn Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the developme...

2021-11-16 00:00 1702

R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved

BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) ofChina has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate...

2021-11-15 22:47 1941
1 ... 162163164165166167168 ... 275

Week's Top Stories